rs2241767 — ADIPOQ +349A>G

Intronic variant in the adiponectin gene associated with lower circulating adiponectin levels, increased type 2 diabetes susceptibility in overweight individuals, and elevated subclinical cardiovascular risk; the G allele confers reduced adiponectin secretion and higher metabolic syndrome risk

See your personal result for ADIPOQ

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ADIPOQ rs2241767 — When Your Fat Tissue Sends Weaker Signals

Adiponectin is one of the most important hormones your body makes — and unlike most hormones, it is produced exclusively by fat cells. This may seem counterintuitive: how can fat tissue secrete a hormone that protects against the very diseases associated with excess fat? The answer lies in adiponectin's remarkable properties: it simultaneously suppresses hepatic glucose production, enhances skeletal muscle fatty acid oxidation, and reduces vascular inflammation. People with high adiponectin levels have lower rates of type 2 diabetes, less coronary artery disease, and better insulin sensitivity regardless of their body weight. The rs2241767 variant is one of several intronic polymorphisms in the ADIPOQ gene that quietly alters how much of this protective hormone your fat cells release.

rs2241767 sits in intron 2 of ADIPOQ11 intron 2 of ADIPOQ
The second non-coding segment of the adiponectin gene, 135 nucleotides downstream of the second coding exon, at GRCh38 position chr3:186853407, where the A-to-G substitution on the plus strand (c.214+135A>G) affects regulatory sequences that govern adiponectin transcription or mRNA processing. The G allele has a global frequency of roughly 11%, but with striking population variation: it reaches 29% in East Asian populations while falling to just 4% in African populations, making ancestry-aware interpretation important.

The Mechanism

Intronic variants like rs2241767 can influence gene expression through multiple mechanisms: altered binding of transcription factors to intronic enhancer elements, changes in pre-mRNA splicing efficiency22 pre-mRNA splicing efficiency
The process by which introns are removed from precursor RNA — variants near splice regulatory sequences can subtly shift splice site usage even if they're not at the consensus splice site itself, or effects on local chromatin accessibility. The rs2241767 G allele lies in a region of ADIPOQ intron 2 that is in partial linkage disequilibrium33 linkage disequilibrium
The tendency for nearby genetic variants to be inherited together, meaning rs2241767 may tag other functional variants in the same haplotype block with the exon 2 synonymous variant rs2241766 (T45G), which is separately associated with reduced mRNA stability and lower adiponectin secretion.

The net result of carrying the G allele at rs2241767 is measurably lower circulating adiponectin. Because adiponectin acts as a brake on hepatic glucose output and a stimulant of skeletal muscle AMPK44 AMPK
AMP-activated protein kinase — a master regulator of cellular energy status that is directly activated by adiponectin and mimics some of the metabolic effects of exercise and calorie restriction activation, reduced adiponectin translates to greater insulin resistance under conditions of metabolic stress — particularly in individuals who are already carrying excess adipose tissue.

The Evidence

The association between rs2241767 and metabolic outcomes has been replicated across diverse populations. In a Chinese Han case-control study55 Chinese Han case-control study
1,105 type 2 diabetes patients and 1,107 controls by Du et al. (2011), AG/GG carriers showed significantly lower serum adiponectin levels than AA homozygotes (P=0.044), and the AG genotype was associated with a 32% higher risk of type 2 diabetes specifically in obese participants (adjusted OR 1.32, 95% CI 1.03–1.69). The interaction with obesity is biologically coherent: when adipose tissue is already inflamed and dysfunctional, impaired adiponectin secretion from the G allele removes a critical compensatory mechanism.

Cardiovascular findings from the MESA study66 MESA study
Multi-Ethnic Study of Atherosclerosis, a large prospective cohort of 6,814 participants free of clinical cardiovascular disease at enrollment by Wassel et al. (2011) showed that in African American participants, AG/GG carriers had a 36% higher prevalence of coronary artery calcification77 coronary artery calcification
Calcium deposits in coronary artery walls detected by CT scan, a direct measure of subclinical atherosclerosis and a strong predictor of future heart attack risk (P=0.0001) and significantly greater carotid intima-media thickness88 carotid intima-media thickness
An ultrasound measure of artery wall thickness in the carotid arteries, reflecting cumulative atherosclerotic burden (P=0.0043) compared to AA carriers. These findings were specific to African Americans and Hispanics — the G allele is sufficiently rare in those populations that even modest effects remain detectable, while in European and Chinese populations the signal is diluted by other adiponectin-pathway variants at higher frequency.

In a South Indian population study99 South Indian population study
1,100 type 2 diabetic patients and 1,100 normoglycemic controls from the Chennai Urban Rural Epidemiology Study by Ramya et al. (2013), rs2241767 showed an independent association with central obesity — the abdominal fat deposition pattern most strongly linked to metabolic syndrome — distinct from its effects on diabetes risk per se. In Mexican American families from the San Antonio Family Heart Study, rs2241767 was significantly associated with skin fold thickness1010 rs2241767 was significantly associated with skin fold thickness
A surrogate for subcutaneous adiposity and fat distribution (P=0.013) in the context of insulin resistance syndrome phenotypes, suggesting the variant's effects on fat distribution may be separable from glycemic effects.

The broader genetic architecture of the ADIPOQ locus — established as the dominant single genetic determinant of plasma adiponectin levels1111 established as the dominant single genetic determinant of plasma adiponectin levels
Explaining approximately 6.7% of phenotypic variance in Europeans across a GWAS of 18,454 subjects — means rs2241767's effects are best understood as part of a haplotype. The variant is in partial LD with rs2241766, rs1501299, and rs266729, and the combination of risk alleles across the locus has a larger impact on adiponectin than any single variant alone.

Practical Actions

Carriers of the G allele cannot directly modify the upstream genetic impairment in adiponectin secretion, but several nutrient and lifestyle factors can raise circulating adiponectin levels independent of genotype. Long-chain omega-3 fatty acids (EPA and DHA) are the best-supported dietary upregulators of adiponectin expression in adipose tissue — multiple randomized trials show that 2–4 g EPA/DHA per day raises adiponectin by 10–25%, with the effect strongest in people with low baseline adiponectin. Magnesium deficiency independently suppresses adiponectin secretion and worsens insulin resistance through AMPK-dependent pathways; AG/GG carriers who are also magnesium-insufficient compound both deficiencies.

Because the G allele's effect on T2D risk is specifically amplified in overweight individuals, the practical implication for G carriers is that the genotype-environment interaction is the key risk driver. Keeping adipose tissue lean and metabolically healthy eliminates most of the excess risk — but the mechanism is different from the generic "maintain healthy weight" advice: the G allele increases the metabolic penalty per unit of excess adiposity because each kilogram of extra fat tissue secretes less adiponectin in G carriers than in AA carriers.

Monitoring fasting insulin and adiponectin levels directly provides useful biomarker feedback for G carriers — these tests quantify the actual metabolic consequence of the variant and can motivate and track intervention effectiveness before glucose tolerance deteriorates.

Interactions

rs2241767 is in partial LD with two other ADIPOQ variants already in the GeneOps database: rs2241766 (T45G, exon 2 synonymous) and rs1501299 (+276G>T, intron 2). Individuals carrying risk alleles at all three variants — which tend to cluster on the same haplotype — show substantially greater reduction in adiponectin levels than any single variant predicts. The combined low-adiponectin haplotype interacts particularly strongly with excess adiposity and with rs266729 (the -11365C>G promoter variant associated with reduced ADIPOQ transcription). The compounding of these effects within the ADIPOQ locus is the basis for proposing interaction actions across these variants.

Nutrient Interactions

omega-3 fatty acids altered_metabolism
magnesium increased_need

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal Adiponectin Secretion Normal

Standard adiponectin secretion — no increased metabolic risk from this variant

You carry two copies of the common A allele at rs2241767. This means your ADIPOQ gene does not carry this particular intronic variant that reduces adiponectin secretion efficiency. About 79% of people of European descent share this genotype. Your baseline adiponectin secretion from this variant is unaffected, though other ADIPOQ variants and lifestyle factors still influence your total circulating adiponectin levels.

AG Reduced Adiponectin Output Intermediate

One G allele — modestly lower adiponectin and increased metabolic risk under caloric surplus

The G allele at this intronic position alters a regulatory element in ADIPOQ intron 2, reducing the efficiency of adiponectin gene expression or mRNA processing in adipocytes. Because adiponectin suppresses hepatic glucose production and activates AMPK in skeletal muscle, lower adiponectin creates a subtle impairment in insulin sensitization that becomes clinically meaningful when adipose tissue is stressed by caloric excess.

Subclinical cardiovascular findings from the MESA cohort (n=2,847) also documented a 36% higher prevalence of coronary artery calcification in AG/GG African American carriers (P=0.0001), with elevated carotid intima-media thickness as a second independent marker of early atherosclerotic burden. These effects underscore that lower adiponectin from this variant has consequences beyond glycemic control alone.

GG Low Adiponectin Secretion Reduced

Two G alleles — substantially lower adiponectin secretion and meaningful metabolic and cardiovascular risk

With two G alleles, both copies of your ADIPOQ gene have impaired intron 2 regulatory function, resulting in lower adiponectin mRNA production and reduced circulating adiponectin across the board. The dose-response relationship is clear: GG individuals have lower adiponectin than AG individuals, who in turn have lower adiponectin than AA individuals, following a codominant inheritance pattern.

The clinical consequences compound: reduced adiponectin means less AMPK activation in skeletal muscle (reducing glucose uptake and fatty acid oxidation), less suppression of hepatic gluconeogenesis (higher fasting blood glucose), and more vascular inflammation through reduced adiponectin's anti-inflammatory signaling on endothelial cells. The MESA study's cardiovascular findings — 36% higher coronary artery calcification in AG/GG combined — reflect the early-stage vascular consequence of chronically lower adiponectin.

In practical terms, GG carriers face a risk profile that has two components: a metabolic component (higher T2D risk, especially with excess weight) and a vascular component (accelerated subclinical atherosclerosis detectable before any symptoms). Addressing both through adiponectin-raising interventions and direct biomarker monitoring is the most targeted response to this genotype.